Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, September 30, 2021

Study identifies protein important for motor coordination and exercise performance

 Well your doctor should have been doing something like this from May 2017 already to prevent your muscle atrophy.

'Exercise-in-a-pill' boosts athletic endurance by 70 percent May 2017 

Or this?

A replacement for exercise? January 2020 

For each day a patient is in hospital lying in bed with minimal activity approximately 13% of muscular strength is lost (Ellis, Jackson, Liu, Molloy, & Paterson, 2013). (Correcting this is your doctors' responsibility. Don't let her weasel out of that responsibility.)

The latest here:

Study identifies protein important for motor coordination and exercise performance

Karolinska Institutet News|September 29, 2021

Researchers at Karolinska Institutet in Sweden have identified a protein that improves muscular metabolism, motor coordination and exercise performance in mice. The findings, published in Cell Metabolism, could be of therapeutic value for patients with muscle and neurological diseases, such as ALS.

Muscle health is a major determinant of overall health and the best way to keep muscles healthy is to exercise regularly. However, for some patients with debilitating diseases, exercise is not always possible. For that reason, researchers are looking for molecules that can by themselves bring about some of the benefits of physical exercise.

In the current study, researchers at Karolinska Institutet wanted to know how a muscle-produced protein called neurturin affects neuromuscular function. Understanding what signals mediate motor neuron and muscle communication is essential for exploring new treatments for muscle-related and neurological diseases, such as amyotrophic lateral sclerosis (ALS).


“We wanted to know if muscles can talk back to motor neurons by sending their own messages, and to find out what are the consequences of those signals,” saysJorge Ruas, professor at theDepartment of Physiology and Pharmacology, Karolinska Institutet, and corresponding author.

The researchers found that mice that were genetically modified to produce more neurturin in muscle cells significantly improved their muscle metabolism, exercise performance and motor coordination compared to regular mice.

Changed motor neuron identity

The high neurturin mice also had an increased number of motor neurons of a type that is more resistant to degeneration in diseases like ALS.

“To find out that a molecule released from muscle fibres can actually change motor neuron identity, shifting them to a type that is associated with more resistance to degeneration opens really exciting possibilities for the future,” Jorge Ruas adds.

As a next step, the researchers are hoping to explore the therapeutic possibilities of neurturin in mouse models of type 2 diabetes, obesity and ALS. They are also working on modifying the administration of neurturin to allow it to be used as a potential drug.

Could be of therapeutic value

“There’s much to be done, but we believe this could be of therapeutic value for patients with metabolic and neuromuscular diseases, such as type 2 diabetes and ALS,” says the study’s first authorJorge Correia, researcher at the Department of Physiology and Pharmacology, Karolinska Institutet.

The researchers note there were some limitations to the study, including the use of genetic tools and viral vectors to increase the levels of neurturin, which isn’t directly applicable from a therapeutic standpoint.


This study was financed by the Swedish Research Council, the Novo Nordisk Foundation, the Swedish Diabetes Foundation, the Strategic Research Program (SRP) in Diabetes, and The Lars Hiertas Memorial Foundation. Sandra Kleiner, Michael Stec and Naveen Khan are employees and shareholders of Regeneron Pharmaceuticals, Inc. Jorge Lira Ruas is a consultant for Bayer AG. There are no other reported conflicts of interest.

To read more, click here

 

No comments:

Post a Comment